European Journal of Pharmacology, 238 (1993) 451–454
© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999/93/$06.00

Author index

Abrahams, T.P., Taveira DaSilva, A.M., Hamosh, P., McManigle, J.E. and Gillis, R.A.
Cardiorespiratory effects produced by blockade of excitatory amino acid receptors in cats (238) 223

Abrahams, Z., Chang, S.D. and Sutter, M.C.
Stimulant effect of human gamma globulin on smooth muscle preparations (238) 435

Abram, T.S., see Gardiner, P.J. (238) 19

Adams, M.E., see Burke, S.P. (238) 383

Adler, L., see Huether, G. (238) 249

Amico-Roxas, M., see Clementi, G. (238) 101

Ashida, S.-i., see Watabe, S. (238) 303

Barone, D., see Bianchi, G. (238) 327

Bereznai, B., see Deckert, J. (238) 131

Betito, K., Diorio, J. and Boksa, P.
Brief cortisol exposure elevates adrenal phenylethanolamine N-methyltransferase after a necessary lag period (238) 273

Bianchi, G., Barone, D., Lanzarotti, E., Tettamanti, R., Porta, R., Moltrasio, D., Cedro, A., Salvetti, L., Mantovani, M. and Prino, G.
Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist (238) 327

Bigg, D.C.H., see Sleight, A.J. (238) 407

Biggio, G., see Imperato, A. (238) 135

Boksa, P., see Betito, K. (238) 273

Boukili, M.A., see Cunha, F.Q. (238) 47

Boulton, A.A., see Zhu, M.-Y. (238) 157

Braga Da Motta, J.I., see Cunha, F.Q. (238) 47

Brewster, M., see Gater, P.R. (238) 59

Brioni, J.D., O'Neill, A.B., Kim, D.J.B. and Decker, M.W.
Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test (238) 1

Bungardt, E., see Eltze, M. (238) 343

Burakoff, R., see Goldhill, J. (238) 387

Burke, S.P., Adams, M.E. and Taylor, C.P.
Inhibition of endogenous glutamate release from hippocampal tissue by Ca^{2+} channel toxins (238) 383

Cadieux, A., see Dumont, Y. (238) 37

Calignano, A., see Persico, P. (238) 105

Caruso, A., see Clementi, G. (238) 101

Cedro, A., see Bianchi, G. (238) 327

Cervo, L., Rossi, C. and Samanin, R.
Clonidine-induced place preference is mediated by α_2-adrenoceptors outside the locus coeruleus (238) 201

Chaki, S., see Tanaka, M. (238) 89

Chang, S.D., see Abrahams, Z. (238) 435

Clark, W.A., see Morrow, B.A. (238) 255

Clementi, G., Amico-Roxas, M., Caruso, A., Cutuli, V.M.C., Maugeri, S. and Prato, A.
Protective effects of calcitonin gene-related peptide in different experimental models of gastric ulcers (238) 101

Coelho, M.M., Pelá, I.R. and Rothwell, N.J.
Dexamethasone inhibits the pyrogenic activity of prostaglandin $F_{2\alpha}$, but not prostaglandin E_2 (238) 391

Cunha, F.Q., Boukili, M.A., Braga Da Motta, J.I., Vargaftig, B.B. and Ferreira, S.H.
Blockade by fenspiride of endotoxin-induced neutrophil migration in the rat (238) 47

Cuthbert, N.J., see Gardiner, P.J. (238) 19

Cutuli, V.M.C., see Clementi, G. (238) 101

Davis, J.M., see Javaid, J.I. (238) 425

Dazzi, L., see Imperato, A. (238) 135

Decker, M.W., see Brioni, J.D. (238) 1

Deckert, J., Bereznai, B., Hennemann, A., Gsell, W., Götz, M., Fritze, J. and Riederer, P.
Nimodipine inhibits [^{3}H]nitrobenzylthioinosine binding to the adenosine transporter in human brain (238) 131

Diener, M. and Scharrer, E.
The leukotriene D_4 receptor blocker, SK&F 104353, inhibits volume regulation in isolated crypts from the rat distal colon (238) 217

Diorio, J., see Betito, K. (238) 273

Dodd, P.R., see Westphalen, R.I. (238) 399

Domenech, R., Macho, P., Penna, M., Schwarze, H., Huidobro-Toro, J.P. and Thumala, A.
Role of endothelium-derived relaxing factor on coronary blood flow regulation in the dog (238) 53

Donovan, V., see Goldhill, J. (238) 387

Dumont, Y., Satoh, H., Cadieux, A., Taoudi-Benchekroun, M., Pheng, L.-H., St-Pierre, S., Fournier, A. and Quirion, R.
Evaluation of truncated neuropeptide Y analogues with modifications of the tyrosine residue in position 1 on Y_1, Y_2 and Y_3 receptor sub-types (238) 37

Ekonsalo, T., see Riekkinen, Jr., P. (238) 263

Eltze, M., Ullrich, B., Mutschler, E., Moser, U., Bungardt, E., Friebe, T., Gubitz, C., Tacke, R. and Lambrecht, G.
Characterization of muscarinic receptors mediating vasodilation in rat perfused kidney (238) 343

Ferreira, S.H., see Cunha, F.Q. (238) 47

Fournier, A., see Dumont, Y. (238) 37

Franco-Cereceda, A., Källner, G. and Lundberg, J.M.
Capsazepine-sensitive release of calcitonin gene-related peptide from C-fibre afferents in the guinea-pig heart by low pH and lactic acid (238) 311

Friebe, T., see Eltze, M. (238) 343

Frittoli, E., see Gobbi, M. (238) 9

Fritze, J., see Deckert, J. (238) 131

Fujisawa, M., Miyamoto, O., Itano, T., Tokuda, M., Matsui, H., Nagao, S., Negi, T. and Hatase, O.
Ceruletide suppresses rotational behavior in lesioned rats via CCK_A receptors (238) 127

Fukuda, T., see Irifune, M. (238) 235

Gardiner, P.J., Norman, P., Cuthbert, N.J., Tudhope, S.R. and Abram, T.S.
Characterisation of the peptido-leukotriene receptor PL2 on the ferret spleen strip (238) 19

Garret, C., see Moussaoui, S.M. (238) 421
Gater, P.R., Paciorek, P.M., McKean, J.C., Wilson, K., Brewster, M. and Waterfall, J.F.
The inhibitory effects of Ro 31-6930 and BRL 38227 on cholinergically-mediated bronchoconstriction in the guinea-pig (238) 59
Gessa, G.L., see Imperato, A. (238) 135
Gessa, G.L., see Imperato, A. (238) 377
Gillis, R.A., see Abrahams, T.P. (238) 223
Gobbi, M., Frittoli, E., Uslenghi, A. and Mennini, T.
Evidence of an exocytotic-like release of [^{3}H]5-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes (238) 9
Goldhill, J., Zhao, L., Xu, Y., Donovan, V. and Burakoff, R.
Defective stimulation of cyclic AMP by prostaglandin E_2 in colonic epithelial cells in colitis (238) 387
Götz, M., see Deckert, J. (238) 131
Gsell, W., see Deckert, J. (238) 131
Gubitz, C., see Eltze, M. (238) 343

Hamosh, P., see Abrahams, T.P. (238) 223
Hatake, K., Wakabayashi, I. and Hishida, S.
Mechanism of inhibitory action of ethanol on endothelium-dependent relaxation in rat aorta (238) 441
Hatase, O., see Fujisawa, M. (238) 127
Hennemann, A., see Deckert, J. (238) 131
Hirai, K., see Miyamoto, M. (238) 181
Hishida, S., see Hatake, K. (238) 441
Hjorth, S. and Pettersson, G.
5-HT_{1A} autoreceptor-mediated effects of the amperozide congeners, FG5865 and FG5893, on rat brain 5-hydroxytryptamine neurochemistry in vivo (238) 357
Högberg, T., see Mohell, N. (238) 121
Hönack, D., see Löscher, W. (238) 191
Huang, X. and Nichols, D.E.
5-HT_2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits (238) 291
Huether, G., Poeggeler, B., Adler, L. and Rüther, E.
Effects of indirectly acting 5-HT receptor agonists on circulating melatonin levels in rats (238) 249
Huidobro-Toro, J.P., see Domenech, R. (238) 53

Ichihara, K., Okumura, K., Mori, H. and Nagasaka, M.
Effects of MPC-1304, a novel Ca^{2+} entry blocker, on α-adrenoceptor-mediated pressor responses in pithed rats (238) 283
Ichihara, K., see Miyoshi, K. (238) 139
Iga, Y., Yoshioka, M., Togashi, H. and Saito, H.
Inhibitory action of N^{ω}-nitro-L-arginine methyl ester on in vivo long-term potentiation in the rat dentate gyrus (238) 395
Imagawa, Y., see Tanaka, M. (238) 89
Imai, M., see Shinkawa, T. (238) 317
Imperato, A., Dazzi, L., Obinu, M.C., Gessa, G.L. and Biggio, G.
Inhibition of hippocampal acetylcholine release by benzodiazepines: antagonism by flumazenil (238) 135
Imperato, A., Obinu, M.C. and Gessa, G.L.
Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus (238) 377
Irifune, M., Nomoto, M. and Fukuda, T.
Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets (238) 235
Itano, T., see Fujisawa, M. (238) 127
Ito, H., see Kamato, T. (238) 369
Itoshima, T., see Masui, A. (238) 297

Jackson, D.M., see Mohell, N. (238) 121
Javaid, J.I., Sahni, S.K., Pandey, S.C. and Davis, J.M.
Repeated cocaine administration does not affect 5-HT receptor subtypes (5-HT_{1A}, 5-HT_2) in several rat brain regions (238) 425
Juorio, A.V., see Zhu, M.-Y. (238) 157

Kaku, S., see Tanaka, M. (238) 93
Källner, G., see Franco-Cereceda, A. (238) 311
Kamato, T., Ito, H., Nagakura, Y., Nishida, A., Yuki, H., Yamano, M. and Miyata, K.
Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets (238) 369
Kamei, H., see Miyoshi, K. (238) 139
Kanda, A., see Miyoshi, K. (238) 139
Kato, K., see Miyamoto, M. (238) 181
Kato, N., see Masui, A. (238) 297
Kim, D.J.B., see Brioni, J.D. (238) 1
Kobayashi, M., see Ohno, M. (238) 117
Koek, W., see Sleight, A.J. (238) 407
Kovács, G.L.
α-Atrial natriuretic peptide attenuates ethanol withdrawal symptoms (238) 417
Kreeger, J.S. and Larson, A.A.
Substance P-(1–7), a substance P metabolite, inhibits withdrawal jumping in morphine-dependent mice (238) 111
Kurosawa, M., Yodonawa, S. and Tsukagoshi, H.
Inhibition of 9α,11β-prostaglandin F_2-induced bronchial hyperresponsiveness by thromboxane A_2 receptor antagonists in guinea pigs (238) 335
Kwan, C.-Y. and Wang, Z.-L.
Tetrandrine: a vasodilator of medicinal herb origin with a novel contractile effect on dog saphenous vein (238) 431

Lambrecht, G., see Eltze, M. (238) 343
Lammintausta, R., see Riekkinen, Jr., P. (238) 263
Lanzarotti, E., see Bianchi, G. (238) 327
Larson, A.A., see Kreeger, J.S. (238) 111
Le Prado, N., see Moussaoui, S.M. (238) 421
Löscher, W. and Hönack, D.
Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats (238) 191
Lundberg, J.M., see Franco-Cereceda, A. (238) 311

Macho, P., see Domenech, R. (238) 53
Malmberg, Å., see Mohell, N. (238) 121
Mancuso, F., see Persico, P. (238) 105
Mantovani, M., see Bianchi, G. (238) 327
Masui, A., Kato, N., Itoshima, T., Tsunashima, K., Nakajima, T. and Yanaihara, N.
Scratching behavior induced by bombesin-related peptides. Comparison of bombesin, gastrin-releasing peptide and phyllolitorins (238) 297
Matsui, H., see Fujisawa, M. (238) 127
Maugeri, S., see Clementi, G. (238) 101
McKean, J.C., see Gater, P.R. (238) 59
McManigle, J.E., see Abrahams, T.P. (238) 223
Mennini, T., see Gobbi, M. (238) 9
Millan, M.J. and Seguin, L.
(+)-HA 966, a partial agonist at the glycine site coupled to NMDA receptors, blocks formalin-induced pain in mice (238) 445
Miyake, H., see Miyoshi, K. (238) 139
Miyamoto, M., Hirai, K., Takahashi, H., Kato, K., Nishiyama, M., Okada, H. and Nagaoka, A.
Effects of sustained release formulation of thyrotropin-releasing hormone on learning impairments caused by scopolamine and AF64A in rodents (238) 181
Miyamoto, O., see Fujisawa, M. (238) 127
Miyata, K., see Kamato, T. (238) 369
Miyoshi, K., Kanda, A., Miyake, H., Ichihara, K., Kamei, H. and Nagasaka, M.
MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action (238) 139

Mohell, N., Sällemark, M., Rosqvist, S., Malmberg, Å., Högberg, T. and Jackson, D.M.
Binding characteristics of remoxipride and its metabolites to dopamine D_2 and D_3 receptors (238) 121
Moltrasio, D., see Bianchi, G. (238) 327
Mori, H., see Ichihara, K. (238) 283
Morrow, B.A., Clark, W.A. and Roth, R.H.
Stress activation of mesocorticolimbic dopamine neurons: effects of a glycine/NMDA receptor antagonist (238) 255
Mos, J., Olivier, B., Poth, M., Van Oorschot, R. and Van Aken, H.
The effects of dorsal raphe administration of eltoprazine, TFMPP and 8-OH-DPAT on resident intruder aggression in the rat (238) 411
Moser, U., see Eltze, M. (238) 343
Moussaoui, S.M., Philippe, L., Le Prado, N. and Garret, C.
Inhibition of neurogenic inflammation in the meninges by a non-peptide NK_1 receptor antagonist, RP 67580 (238) 421
Mulvany, M.J., see Prieto, D. (238) 27
Muramatsu, M., see Tanaka, M. (238) 89
Muramatsu, M., see Tanaka, M. (238) 93
Mutschler, E., see Eltze, M. (238) 343

Nagakura, Y., see Kamato, T. (238) 369
Nagao, S., see Fujisawa, M. (238) 127
Nagaoka, A., see Miyamoto, M. (238) 181
Nagasaka, M., see Ichihara, K. (238) 283
Nagasaka, M., see Miyoshi, K. (238) 139
Nakajima, T., see Masui, A. (238) 297
Nakakuki, M., see Shinkawa, T. (238) 317
Negi, T., see Fujisawa, M. (238) 127
Netzer, R., Pflimlin, P. and Trube, G.
Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons (238) 209
Neuman, R.S., see Rahman, S. (238) 173
Nichols, D.E., see Huang, X. (238) 291
Nielsen-Kudsk, J.E., see Pedersen, C.M. (238) 75
Nihonyanagi, K. and Oba, T.
Gold ion induces contraction in frog skeletal muscle fibers (238) 149
Nishida, A., see Kamato, T. (238) 369
Nishijima, K., see Shinkawa, T. (238) 317
Nishiyama, M., see Miyamoto, M. (238) 181
Nomoto, M., see Irifune, M. (238) 235
Norman, P., see Gardiner, P.J. (238) 19
Notsu, T., see Shinkawa, T. (238) 317
Nyborg, N.C.B., see Prieto, D. (238) 27

Oba, T., see Nihonyanagi, K. (238) 149
Obinu, M.C., see Imperato, A. (238) 135
Obinu, M.C., see Imperato, A. (238) 377
Ohno, M., Yamamoto, T., Kobayashi, M. and Watanabe, S.
Impairment of working memory induced by scopolamine in rats with noradrenergic DSP-4 lesions (238) 117
Okada, H., see Miyamoto, M. (238) 181
Okumura, K., see Ichihara, K. (238) 283
Okuyama, S., see Tanaka, M. (238) 89
Olivier, B., see Mos, J. (238) 411
O'Neill, A.B., see Brioni, J.D. (238) 1
Otomo, S., see Tanaka, M. (238) 89
Otomo, S., see Tanaka, M. (238) 93

Paciorek, P.M., see Gater, P.R. (238) 59
Pandey, S.C., see Javaid, J.I. (238) 425
Panizzon, K.L., see Wallis, R.A. (238) 165
Paterson, I.A., see Zhu, M.-Y. (238) 157
Pedersen, C.M., Thirstrup, S. and Nielsen-Kudsk, J.E.
Smooth muscle relaxant effects of propofol and ketamine in isolated guinea-pig trachea (238) 75
Pelá, I.R., see Coelho, M.M. (238) 391
Penna, M., see Domenech, R. (238) 53
Persico, P., Calignano, A., Mancuso, F. and Sorrentino, L.
Involvement of NK receptors and β-adrenoceptors in nitric oxide-dependent relaxation of rabbit aorta rings following electrical-field stimulation (238) 105
Pettersson, G., see Hjorth, S. (238) 357
Pflimlin, P., see Netzer, R. (238) 209
Pheng, L.-H., see Dumont, Y. (238) 37
Philippe, L., see Moussaoui, S.M. (238) 421
Poeggeler, B., see Huether, G. (238) 249
Porkka-Heiskanen, T., see Stenberg, D. (238) 241
Porta, R., see Bianchi, G. (238) 327
Poth, M., see Mos, J. (238) 411
Prato, A., see Clementi, G. (238) 101
Prieto, D., Mulvany, M.J. and Nyborg, N.C.B.
Effects of (+)-S-12967 and (−)-S-12968, two enantiomers of a new slow-acting 1,4-dihydropyridine, on rat coronary resistance arteries (238) 27
Prino, G., see Bianchi, G. (238) 327

Quirion, R., see Dumont, Y. (238) 37

Rabkin, S.W.
Lisinopril increases the recovery during reoxygenation and resistance to oxidative damage in cardiomyocytes (238) 81
Rahman, S. and Neuman, R.S.
Multiple mechanisms of serotonin 5-HT_2 receptor desensitization (238) 173
Riederer, P., see Deckert, J. (238) 131
Riekkinen, Jr., P., Lammintausta, R., Ekonsalo, T. and Sirviö, J.
The effects of α_2-adrenoceptor stimulation on neocortical EEG activity in control and 6-hydroxydopamine dorsal noradrenergic bundle-lesioned rats (238) 263
Rosqvist, S., see Mohell, N. (238) 121
Rossi, C., see Cervo, L. (238) 201
Roth, R.H., see Morrow, B.A. (238) 255
Rothwell, N.J., see Coelho, M.M. (238) 391
Rüther, E., see Huether, G. (238) 249

Sahni, S.K., see Javaid, J.I. (238) 425
Saito, H., see Iga, Y. (238) 395
Sällemark, M., see Mohell, N. (238) 121
Salvetti, L., see Bianchi, G. (238) 327
Samanin, R., see Cervo, L. (238) 201
Sandström, P.-E. and Sehlin, J.
Evidence for separate Na^+, K^+, Cl^- and K^+, Cl^- co-transport systems in mouse pancreatic β-cells (238) 403
Satoh, H., see Dumont, Y. (238) 37
Scharrer, E., see Diener, M. (238) 217
Schwarze, H., see Domenech, R. (238) 53
Seguin, L., see Millan, M.J. (238) 445
Sehlin, J., see Sandström, P.-E. (238) 403
Shinkawa, T., Yamasaki, F., Notsu, T., Nakakuki, M., Nishijima, K., Yoshitomi, K. and Imai, M.
Loop and distal actions of a novel diuretic, M17055 (238) 317
Sirviö, J., see Riekkinen, Jr., P. (238) 263
Sleight, A.J., Koek, W. and Bigg, D.C.H.
Binding of antipsychotic drugs at α_{1A}- and α_{1B}-adrenoceptors: risperidone is selective for the α_{1B}-adrenoceptors (238) 407
Sorrentino, L., see Persico, P. (238) 105
St-Pierre, S., see Dumont, Y. (238) 37

Stenberg, D., Porkka-Heiskanen, T. and Toppila, J.
α_2-Adrenoceptors and vigilance in cats: antagonism of medetomidine sedation by atipamezole (238) 241
Sutter, M.C., see Abrahams, Z. (238) 435

Tacke, R., see Eltze, M. (238) 343
Takahashi, H., see Miyamoto, M. (238) 181
Tanaka, M., Chaki, S., Imagawa, Y., Okuyama, S., Muramatsu, M. and Otomo, S.
FH-510, a potent and selective ligand for rat brain σ recognition sites (238) 89
Tanaka, M., Kaku, S., Muramatsu, M. and Otomo, S.
Binding of [^{3}H]FH-510 to σ ligand recognition sites in guinea-pig brain membranes (238) 93
Taoudi-Benchekroun, M., see Dumont, Y. (238) 37
Taveira DaSilva, A.M., see Abrahams, T.P. (238) 223
Taylor, C.P., see Burke, S.P. (238) 383
Tettamanti, R., see Bianchi, G. (238) 327
Thalody, G.P., see Wiener, H.L. (238) 65
Thirstrup, S., see Pedersen, C.M. (238) 75
Thumala, A., see Domenech, R. (238) 53
Togashi, H., see Iga, Y. (238) 395
Tokuda, M., see Fujisawa, M. (238) 127
Toppila, J., see Stenberg, D. (238) 241
Trube, G., see Netzer, R. (238) 209
Tsukagoshi, H., see Kurosawa, M. (238) 335
Tsunashima, K., see Masui, A. (238) 297
Tudhope, S.R., see Gardiner, P.J. (238) 19

Ullrich, B., see Eltze, M. (238) 343
Uslenghi, A., see Gobbi, M. (238) 9

Van Aken, H., see Mos, J. (238) 411
Van Oorschot, R., see Mos, J. (238) 411
Vargaftig, B.B., see Cunha, F.Q. (238) 47

Wakabayashi, I., see Hatake, K. (238) 441
Wallis, R.A. and Panizzon, K.L.
Protection from hypoxic and N-methyl-D-aspartate injury with azelastine, a leukotriene inhibitor (238) 165
Wang, Z.-L., see Kwan, C.-Y. (238) 431
Watabe, S., Yamaguchi, H. and Ashida, S.-i.
DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex (238) 303
Watanabe, S., see Ohno, M. (238) 117
Waterfall, J.F., see Gater, P.R. (238) 59
Westphalen, R.I. and Dodd, P.R.
The regeneration of d,l-fenfluramine-destroyed serotonergic nerve terminals (238) 399
Wiener, H.L. and Thalody, G.P.
Kinetic characterization of adenosine A_2 receptor-mediated relaxation in isolated rabbit aorta (238) 65
Wilson, K., see Gater, P.R. (238) 59

Xu, Y., see Goldhill, J. (238) 387

Yamaguchi, H., see Watabe, S. (238) 303
Yamamoto, T., see Ohno, M. (238) 117
Yamano, M., see Kamato, T. (238) 369
Yamasaki, F., see Shinkawa, T. (238) 317
Yanaihara, N., see Masui, A. (238) 297
Yodonawa, S., see Kurosawa, M. (238) 335
Yoshioka, M., see Iga, Y. (238) 395
Yoshitomi, K., see Shinkawa, T. (238) 317
Yuki, H., see Kamato, T. (238) 369

Zhao, L., see Goldhill, J. (238) 387
Zhu, M.-Y., Juorio, A.V., Paterson, I.A. and Boulton, A.A.
Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors (238) 157

European Journal of Pharmacology, 238 (1993) 455–465

© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999/93/$06.00

Key word index

Acetylcholine
DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Scopolamine; Working memory; Reference memory (Ohno, M. (238) 117)

Cocaine; d-Amphetamine; Hippocampus; Caudate nucleus; Dopamine (Imperato, A. (238) 377)

Ethanol; Endothelium; Vasorelaxation; Aorta; (Rat) (Hatake, K. (238) 441)

Acetylcholine release
Hippocampus; Benzodiazepines (Imperato, A. (238) 135)

Adenosine
Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

Adenosine receptors
Purinoceptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

Adenosine A_2 receptors
Kinetics; Antagonism, functional; α_1-Adrenoceptor; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

Adenosine transporters
Nimodipine; [^{3}H]Nitrobenzylthioinosine binding; Parietal cortex (human) (Deckert, J. (238) 131)

Adrenal medulla
Glucocorticoid receptors; Phenylethanolamine N-methyltransferase; Nicotine; Catecholamines (Betito, K. (238) 273)

α_1-Adrenoceptor
Kinetics; Antagonism, functional; Adenosine A_2 receptors; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

α_2-Adrenoceptor agonists
Locus coeruleus; α_2-Adrenoceptor antagonists; High voltage spindle; Slow wave (Riekkinen, Jr., P. (238) 263)

α_2-Adrenoceptor antagonists
Locus coeruleus; α_2-Adrenoceptor agonists; High voltage spindle; Slow wave (Riekkinen, Jr., P. (238) 263)

α-Adrenoceptors
MPC-1304; Ca^{2+} entry blockers; (Pithed rat) (Ichihara, K. (238) 283)

α_{1A}-Adrenoceptors
α_{1B}-Adrenoceptors; Risperidone; Antipsychotics; Receptor binding (Sleight, A.J. (238) 407)

α_{1B}-Adrenoceptors
α_{1A}-Adrenoceptors; Risperidone; Antipsychotics; Receptor binding (Sleight, A.J. (238) 407)

α_2-Adrenoceptors
Clonidine; Place preference; (Rat) (Cervo, L. (238) 201)

Sedation; Anaesthesia; Medetomidine; Atipamezole; (Cat) (Stenberg, D. (238) 241)

β-Adrenoceptors
Substance P; Nitric oxide (NO); Morphine; Substance P receptor antagonists (Persico, P. (238) 105)

AF64A (ethylcholine aziridinium ion)
TRH (thyrotropin-releasing hormone); Sustained release formulation; Scopolamine; Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

Aggression
TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Dorsal raphe (rat) (Mos, J. (238) 411)

Amiloride
M17055; Loop diuretics; Thiazide diuretics; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

cAMP
Cl^- secretion; Colitis; Inflammatory bowel disease; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

Amphetamine
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; 5-HT_2 receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

d-Amphetamine
Cocaine; Hippocampus; Caudate nucleus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

Anaesthesia
α_2-Adrenoceptors; Sedation; Medetomidine; Atipamezole; (Cat) (Stenberg, D. (238) 241)

Anaesthetics
Asthma; Ketamine; Propofol; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

Angiotensin-converting enzyme inhibitors
Lisinopril; Hypoxia; Reoxygenation; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

α-ANP (α-atrial natriuretic peptide)
Ethanol withdrawal; Anti-ANP serum (Kovács, G.L. (238) 417)

Antagonism, functional
Kinetics; Adenosine A_2 receptors; α_1-Adrenoceptor; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

Anti-ANP serum
Ethanol withdrawal; α-ANP (α-atrial natriuretic peptide) (Kovács, G.L. (238) 417)

Antipsychotics
Remoxipride; Remoxipride metabolites; Dopamine receptors; [^{3}H]Raclopride binding (Mohell, N. (238) 121)

α_{1A}-Adrenoceptors; α_{1B}-Adrenoceptors; Risperidone; Receptor binding (Sleight, A.J. (238) 407)

Anxiety
Nicotine; Lobeline; Cytisine; Mecamylamine; Chlorisondamine (Brioni, J.D. (238) 1)

Aorta
Ethanol; Acetylcholine; Endothelium; Vasorelaxation; (Rat) (Hatake, K. (238) 441)

Apneustic breathing
Kynurenic acid; Apnoea; Dizocilpine; Arterial blood pressure; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

Apnoea
Kynurenic acid; Dizocilpine; Arterial blood pressure; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

Aromatic L-amino acid decarboxylase
Dopamine receptors; Striatum; Neuroleptics (Zhu, M.-Y. (238) 157)

Arterial blood pressure
Kynurenic acid; Apnoea; Dizocilpine; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

Arterioles (submucosal)
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Aspartate
Ca^{2+} channels; Exocytosis; Glutamate; GABA (γ-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

Asthma
Anaesthetics; Ketamine; Propofol; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

Atipamezole
α_2-Adrenoceptors; Sedation; Anaesthesia; Medetomidine; (Cat) (Stenberg, D. (238) 241)

Atrium
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Azelastine
Cerebral vascular disease; Ischaemia; Leukotriene; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

Benzodiazepine receptors
DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA release; GABA turnover; $GABA_A$ receptors; (Rat) (Watabe, S. (238) 303)

Benzodiazepines
Acetylcholine release; Hippocampus (Imperato, A. (238) 135)

Binding assays
Neuropeptide Y; Neuropeptide Y receptor sub-types; Truncated analogues; Structure-activity relationships; Bioassays (Dumont, Y. (238) 37)

σ Binding sites
FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol); Radiolabeled ligand binding; (+)-SKF10,047; Stereotyped behaviour (Tanaka, M. (238) 89)

FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride); Radiolabeled ligand binding; Brain (guinea-pig) (Tanaka, M. (238) 93)

Bioassays
Neuropeptide Y; Neuropeptide Y receptor sub-types; Truncated analogues; Structure-activity relationships; Binding assays (Dumont, Y. (238) 37)

Bombesin
Gastrin-releasing peptide (GRP); Phyllolitorin; Scratching behaviour; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

Brain (guinea-pig)
σ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride); Radiolabeled ligand binding (Tanaka, M. (238) 93)

Brain (rat)
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; $5\text{-}HT_{1A}$ autoreceptors (Hjorth, S. (238) 357)

Brain regions (rat)
Cocaine; $5\text{-}HT_{1A}$ receptors; $5\text{-}HT_2$ receptors (Javaid, J.I. (238) 425)

BRL 38227
Ro 31-6930; Bronchoconstriction; Cholinergic; Neurotransmission (Gater, P.R. (238) 59)

Bromocriptine
Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Dopamine D_2 receptor agonists; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

Bronchial hyperresponsiveness
$9\alpha,11\beta$-Prostaglandin F_2; Thromboxane A_2 receptor antagonists (Kurosawa, M. (238) 335)

Bronchoconstriction
Ro 31-6930; BRL 38227; Cholinergic; Neurotransmission (Gater, P.R. (238) 59)

Ca^{2+}
1,4-Dihydropyridine (enantiomers); K^+; pH; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

Tetrandrine; Smooth muscle (vascular); Saphenous vein (dog); Excitation-contraction (Kwan, C.-Y. (238) 431)

Ca^{2+} channel antagonists
MPC-1304; 1,4-Dihydropyridines; Vasodilating action (Miyoshi, K. (238) 139)

Ca^{2+} channel blocking agents
Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; Na^+ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

Ca^{2+} channels
5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Synaptosomes; d-Fenfluramine (Gobbi, M. (238) 9)

Exocytosis; Glutamate; Aspartate; GABA (γ-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

Ca^{2+} channels (L-type)
Gold ion; Perchlorate; Skeletal muscle contraction; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

Ca^{2+} entry blockers
MPC-1304; α-Adrenoceptors; (Pithed rat) (Ichihara, K. (238) 283)

Capsaicin
CGRP (calcitonin gene-related peptide); Capsazepine; Cardiac afferents; Lactic acid (Franco-Cereceda, A. (238) 311)

Capsazepine
CGRP (calcitonin gene-related peptide); Capsaicin; Cardiac afferents; Lactic acid (Franco-Cereceda, A. (238) 311)

Cardiac afferents
CGRP (calcitonin gene-related peptide); Capsaicin; Capsazepine; Lactic acid (Franco-Cereceda, A. (238) 311)

Cardiomyocytes
Angiotensin-converting enzyme inhibitors; Lisinopril; Hypoxia; Reoxygenation; Cardioprotection (Rabkin, S.W. (238) 81)

Cardioprotection
Angiotensin-converting enzyme inhibitors; Lisinopril; Hypoxia; Reoxygenation; Cardiomyocytes (Rabkin, S.W. (238) 81)

Carrageenin
Fenspiride; Tumour necrosis factor; Endotoxin; Neutrophil migration (Cunha, F.Q. (238) 47)

Catecholamines
Glucocorticoid receptors; Adrenal medulla; Phenylethanolamine N-methyltransferase; Nicotine (Betito, K. (238) 273)

Caudate nucleus
Cocaine; d-Amphetamine; Hippocampus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

CCK (cholecystokinin)
Ceruletide; CCK_A receptors; CCK_B receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

CCK_A receptors
Ceruletide; CCK (cholecystokinin); CCK_B receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

CCK_B receptors
Ceruletide; CCK (cholecystokinin); CCK_A receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

Cerebral vascular disease
Azelastine; Ischaemia; Leukotriene; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

Ceruletide
CCK (cholecystokinin); CCK_A receptors; CCK_B receptors; Rotational behaviour; Parkinson's disease (Fujisawa, M. (238) 127)

CGRP (calcitonin gene-related peptide)
Gastric ulcer; Reserpine; Somatostatin (Clementi, G. (238) 101)

Capsaicin; Capsazepine; Cardiac afferents; Lactic acid (Franco-Cereceda, A. (238) 311)

Chlorisondamine
Nicotine; Lobeline; Cytisine; Mecamylamine; Anxiety (Brioni, J.D. (238) 1)

m-Chlorophenylbiguanide
Emesis; $5\text{-}HT_3$ receptor; Cisplatin; YM060 (Kamato, T. (238) 369)

Cholinergic
Ro 31-6930; BRL 38227; Bronchoconstriction; Neurotransmission (Gater, P.R. (238) 59)

Cisplatin
Emesis; $5\text{-}HT_3$ receptor; m-Chlorophenylbiguanide; YM060 (Kamato, T. (238) 369)

Cl^- channels
Regulatory decrease in volume; Colon (rat); Leukotriene D_4 (Diener, M. (238) 217)

Clonidine
α_2-Adrenoceptors; Place preference; (Rat) (Cervo, L. (238) 201)

Cl^- secretion
Colitis; cAMP; Inflammatory bowel disease; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

Cocaine
d-Amphetamine; Hippocampus; Caudate nucleus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

$5\text{-}HT_{1A}$ receptors; $5\text{-}HT_2$ receptors; Brain regions (rat) (Javaid, J.I. (238) 425)

Colitis
Cl^- secretion; cAMP; Inflammatory bowel disease; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

Colon (rat)
Regulatory decrease in volume; Cl^- channels; Leukotriene D_4 (Diener, M. (238) 217)

Coronary artery
1,4-Dihydropyridine (enantiomers); K^+; pH; Ca^{2+}; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Prieto, D. (238) 27)

Co-transport
Pancreatic β-cells; H 25; H 74; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

Cytisine
Nicotine; Lobeline; Mecamylamine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

Defibrotide
Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Trachea (Bianchi, G. (238) 327)

Dentate gyrus
Nitric oxide (NO); Hippocampus; (Rat, in vivo) (Iga, Y. (238) 395)

Desensitization
5-HT (5-hydroxytryptamine, serotonin); Transmitter interaction; Receptor internalization; Protein kinase C (Rahman, S. (238) 173)

Dextromethorphan
Epilepsy; Dextrorphan; Glutamate; Kindling; (Rat) (Löscher, W. (238) 191)

NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; Ca^{2+} channel blocking agents; Na^{+} channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

Dextrorphan
Epilepsy; Dextromethorphan; Glutamate; Kindling; (Rat) (Löscher, W. (238) 191)

1,4-Dihydropyridine (enantiomers)
K^{+}; pH; Ca^{2+}; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

1,4-Dihydropyridines
MPC-1304; Ca^{2+} channel antagonists; Vasodilating action (Miyoshi, K. (238) 139)

Distal nephron segments
M17055; Loop diuretics; Thiazide diuretics; Amiloride; Free water clearance; Microperfusion study (Shinkawa, T. (238) 317)

Dizocilpine
Kynurenic acid; Apnoea; Arterial blood pressure; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide)
GABA uptake; GABA release; GABA turnover; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; $5\text{-}HT_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

DOPAC (3,4-dihydroxyphenylacetic acid)
HA-966; (+)-MK-801; Excitatory amino acids; Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

Dopamine
Cocaine; d-Amphetamine; Hippocampus; Caudate nucleus; Acetylcholine (Imperato, A. (238) 377)

Dopamine D_2 receptor agonists
Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Bromocriptine; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

Dopamine receptors
Remoxipride; Remoxipride metabolites; Antipsychotics; [^{3}H]-Raclopride binding (Mohell, N. (238) 121)

Aromatic L-amino acid decarboxylase; Striatum; Neuroleptics (Zhu, M.-Y. (238) 157)

Dopamine synthesis
5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; $5\text{-}HT_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

Dorsal raphe (rat)
Aggression; TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Mos, J. (238) 411)

DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)
Noradrenaline; Scopolamine; Acetylcholine; Working memory; Reference memory (Ohno, M. (238) 117)

Dura mater
NK_1, receptor antagonist (non-peptide); Neurogenic inflammation; Migraine model; Substance P (Moussaoui, S.M. (238) 421)

EDRF (endothelium-derived relaxing factor)
Hyperemia (reactive); Nitric oxide (NO), Coronary flow regulation; Endothelium (Domenech, R. (238) 53)

Eltoprazine
Aggression; TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Dorsal raphe (rat) (Mos, J. (238) 411)

Emesis
$5\text{-}HT_3$ receptor; Cisplatin; m-Chlorophenylbiguanide; YM060 (Kamato, T. (238) 369)

Endothelium
Hyperemia (reactive); EDRF (endothelium-derived relaxing factor); Nitric oxide (NO), Coronary flow regulation (Domenech, R. (238) 53)

Ethanol; Acetylcholine; Vasorelaxation; Aorta; (Rat) (Hatake, K. (238) 441)

Endotoxin
Fenspiride; Tumour necrosis factor; Carrageenin; Neutrophil migration (Cunha, F.Q. (238) 47)

Epilepsy
Dextromethorphan; Dextrorphan; Glutamate; Kindling; (Rat) (Löscher, W. (238) 191)

Ethanol
Acetylcholine; Endothelium; Vasorelaxation; Aorta; (Rat) (Hatake, K. (238) 441)

Ethanol withdrawal
α-ANP (α-atrial natriuretic peptide); Anti-ANP serum (Kovács, G.L. (238) 417)

Excitation-contraction
Tetrandrine; Smooth muscle (vascular); Saphenous vein (dog); Ca^{2+} (Kwan, C.-Y. (238) 431)

Excitatory amino acids
Kynurenic acid; Apnoea; Dizocilpine; Arterial blood pressure; Apneustic breathing; (Cat) (Abrahams, T.P. (238) 223)

HA-966; (+)-MK-801; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

Exocytosis
Ca^{2+} channels; Glutamate; Aspartate; GABA (γ-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

Fenfluramine
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

d-Fenfluramine
5-HT (5-hydroxytryptamine, serotonin); 5-HT release; Synaptosomes; Ca^{2+} channels (Gobbi, M. (238) 9)

Fenspiride
Tumour necrosis factor; Carrageenin; Endotoxin; Neutrophil migration (Cunha, F.Q. (238) 47)

Fever
Prostaglandins; Glucocorticoids (Coelho, M.M. (238) 391)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide)
FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-HT_{1A} autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-HT_{1A} autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol)
σ Binding sites; Radiolabeled ligand binding; (+)-SKF10,047; Stereotyped behaviour (Tanaka, M. (238) 89)

FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride)
σ Binding sites; Radiolabeled ligand binding; Brain (guinea-pig) (Tanaka, M. (238) 93)

Free water clearance
M17055; Loop diuretics; Thiazide diuretics; Amiloride; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

GABA (γ-aminobutyric acid)
Ca^{2+} channels; Exocytosis; Glutamate; Aspartate; (Rat) (Burke, S.P. (238) 383)

$GABA_A$ receptors
DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA release; GABA turnover; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

GABA release
DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA turnover; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

GABA turnover
DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA uptake; GABA release; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

GABA uptake
DM-9384 (N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide); GABA release; GABA turnover; $GABA_A$ receptors; Benzodiazepine receptors; (Rat) (Watabe, S. (238) 303)

Gamma globulin (human)
Immunoglobulins; Smooth muscle; Immunoglobulin G; Spontaneous contractility (Abrahams, Z. (238) 435)

Gastric ulcer
CGRP (calcitonin gene-related peptide); Reserpine; Somatostatin (Clementi, G. (238) 101)

Gastrin-releasing peptide (GRP)
Bombesin; Phyllolitorin; Scratching behaviour; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

Glucocorticoid receptors
Adrenal medulla; Phenylethanolamine N-methyltransferase; Nicotine; Catecholamines (Betito, K. (238) 273)

Glucocorticoids
Fever; Prostaglandins (Coelho, M.M. (238) 391)

Glutamate
Epilepsy; Dextromethorphan; Dextrorphan; Kindling; (Rat) (Löscher, W. (238) 191)

Ca^{2+} channels; Exocytosis; Aspartate; GABA (γ-aminobutyric acid); (Rat) (Burke, S.P. (238) 383)

Glycine
NMDA (N-methyl-D-aspartate); Pain (Millan, M.J. (238) 445)

Gold ion
Ca^{2+} channels (L-type); Perchlorate; Skeletal muscle contraction; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

H 25
Pancreatic β-cells; H 74; Co-transport; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

H 74
Pancreatic β-cells; H 25; Co-transport; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

pH
1,4-Dihydropyridine (enantiomers); K^+; Ca^{2+}; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

HA-966
(+)-MK-801; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

High voltage spindle
Locus coeruleus; α_2-Adrenoceptor agonists; α_2-Adrenoceptor antagonists; Slow wave (Riekkinen, Jr., P. (238) 263)

Hippocampus
Acetylcholine release; Benzodiazepines (Imperato, A. (238) 135)

Cocaine; d-Amphetamine; Caudate nucleus; Dopamine; Acetylcholine (Imperato, A. (238) 377)

Nitric oxide (NO); Dentate gyrus; (Rat, in vivo) (Iga, Y. (238) 395)

5-HT_{1A} autoreceptors
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; Brain (rat) (Hjorth, S. (238) 357)

5-HT (5-hydroxytryptamine, serotonin)
5-HT release; Synaptosomes; d-Fenfluramine; Ca^{2+} channels (Gobbi, M. (238) 9)

1,4-Dihydropyridine (enantiomers); K^+; pH; Ca^{2+}; Coronary artery; (Rat) (Prieto, D. (238) 27)

Transmitter interaction; Desensitization; Receptor internalization; Protein kinase C (Rahman, S. (238) 173)

Fenfluramine; 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

Dopamine synthesis; 5-HT neurotoxicity; 5-HT_2 receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-HT_{1A} autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

Fenfluramine; Neurotoxins; Nerve terminal regeneration; Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

5-HT metabolism/turnover
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; Microdialysis (in vivo); 5-HT release; 5-HT_{1A} autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

5-HT neurotoxicity
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

5-HT (pool, cytoplasmic)
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

5-HT_3 receptor
Emesis; Cisplatin; m-Chlorophenylbiguanide; YM060 (Kamato, T. (238) 369)

5-HT receptor agonists (indirectly acting)
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin; Tryptophan (Huether, G. (238) 249)

5-HT_{1A} receptors
Cocaine; 5-HT_2 receptors; Brain regions (rat) (Javaid, J.I. (238) 425)

5-HT_2 receptors
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

Cocaine; 5-HT_{1A} receptors; Brain regions (rat) (Javaid, J.I. (238) 425)

5-HT release
5-HT (5-hydroxytryptamine, serotonin); Synaptosomes; d-Fenfluramine; Ca^{2+} channels (Gobbi, M. (238) 9)

Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); Melatonin; Tryptophan (Huether, G. (238) 249)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT_{1A} autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

5-HT synthesis
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-HT_{1A} autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

Hyperemia (reactive)
EDRF (endothelium-derived relaxing factor); Nitric oxide (NO), Coronary flow regulation; Endothelium (Domenech, R. (238) 53)

Hypoxia
Angiotensin-converting enzyme inhibitors; Lisinopril; Reoxygenation; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

ICI 198615
Spleen (ferret); Leukotriene receptors; SK&F 104353; MK571 (Gardiner, P.J. (238) 19)

Ileum
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Immunoglobulin G
Gamma globulin (human); Immunoglobulins; Smooth muscle; Spontaneous contractility (Abrahams, Z. (238) 435)

Immunoglobulins
Gamma globulin (human); Smooth muscle; Immunoglobulin G; Spontaneous contractility (Abrahams, Z. (238) 435)

Inflammatory bowel disease
Cl^- secretion; Colitis; cAMP; Prostaglandin; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

Inosine nucleotides
Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Adenosine; Defibrotide; Trachea (Bianchi, G. (238) 327)

Ischaemia
Azelastine; Cerebral vascular disease; Leukotriene; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

K^+
1,4-Dihydropyridine (enantiomers); pH; Ca^{2+}; 5-HT (5-hydroxytryptamine, serotonin); Coronary artery; (Rat) (Prieto, D. (238) 27)

Ketamine
Asthma; Anaesthetics; Propofol; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

Kidney (perfused, rat)
Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Kindling
Epilepsy; Dextromethorphan; Dextrorphan; Glutamate; (Rat) (Löscher, W. (238) 191)

Kinetics
Antagonism, functional; Adenosine A_2 receptors; α_1-Adrenoceptor; Thoracic aorta (rabbit) (Wiener, H.L. (238) 65)

Kynurenic acid
Apnoea; Dizocilpine; Arterial blood pressure; Apneustic breathing; Excitatory amino acids; (Cat) (Abrahams, T.P. (238) 223)

Lactic acid
CGRP (calcitonin gene-related peptide); Capsaicin; Capsazepine; Cardiac afferents (Franco-Cereceda, A. (238) 311)

Leukotriene
Azelastine; Cerebral vascular disease; Ischaemia; NMDA (N-methyl-D-aspartate) (Wallis, R.A. (238) 165)

Leukotriene D_4
Regulatory decrease in volume; Colon (rat); Cl^- channels (Diener, M. (238) 217)

Leukotriene receptors
Spleen (ferret); ICI 198615; SK&F 104353; MK571 (Gardiner, P.J. (238) 19)

Lisinopril
Angiotensin-converting enzyme inhibitors; Hypoxia; Reoxygenation; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

Lobeline
Nicotine; Cytisine; Mecamylamine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

Locus coeruleus
α_2-Adrenoceptor agonists; α_2-Adrenoceptor antagonists; High voltage spindle; Slow wave (Riekkinen, Jr., P. (238) 263)

Loop diuretics
M17055; Thiazide diuretics; Amiloride; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

M17055
Loop diuretics; Thiazide diuretics; Amiloride; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

MDMA (3,4-methylenedioxymethamphetamine)
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; $5\text{-}HT_2$ receptors; R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine; MMAI (5-methoxy-6-methyl-2-aminoindan) (Huang, X. (238) 291)

Mecamylamine
Nicotine; Lobeline; Cytisine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

Medetomidine
α_2-Adrenoceptors; Sedation; Anaesthesia; Atipamezole; (Cat) (Stenberg, D. (238) 241)

Melatonin
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Tryptophan (Huether, G. (238) 249)

Microdialysis (in vivo)
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); Neurochemical indices (ex vivo); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; 5-HT release; $5\text{-}HT_{1A}$ autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

Microperfusion study
M17055; Loop diuretics; Thiazide diuretics; Amiloride; Free water clearance; Distal nephron segments (Shinkawa, T. (238) 317)

Migraine model
NK_1, receptor antagonist (non-peptide); Dura mater; Neurogenic inflammation; Substance P (Moussaoui, S.M. (238) 421)

MK571
Spleen (ferret); Leukotriene receptors; ICI 198615; SK&F 104353 (Gardiner, P.J. (238) 19)

(+)-MK-801
HA-966; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex; Nucleus accumbens (Morrow, B.A. (238) 255)

MMAI (5-methoxy-6-methyl-2-aminoindan)
Dopamine synthesis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT neurotoxicity; $5\text{-}HT_2$ receptors; MDMA (3,4-methylenedioxymethamphetamine); R-DOI (R-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Amphetamine (Huang, X. (238) 291)

Morphine
Substance P; Nitric oxide (NO); Substance P receptor antagonists; β-Adrenoceptors (Persico, P. (238) 105)

Morphine withdrawal
Substance P; Substance P N-terminus; (Intrathecal) (Kreeger, J.S. (238) 111)

MPC-1304
Ca^{2+} channel antagonists; 1,4-Dihydropyridines; Vasodilating action (Miyoshi, K. (238) 139)

Ca^{2+} entry blockers; α-Adrenoceptors; (Pithed rat) (Ichihara, K. (238) 283)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Bromocriptine; Dopamine D_2 receptor agonists; Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

Muscarinic receptor agonists
Kidney (perfused, rat); Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Muscarinic receptor antagonists
Kidney (perfused, rat); Muscarinic receptor agonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Na^+ channel blocking agents
Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; Ca^{2+} channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

Nerve cell cultures
Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; Ca^{2+} channel blocking agents; Na^+ channel blocking agents; Voltage clamp (Netzer, R. (238) 209)

Nerve terminal regeneration
Fenfluramine; Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

Neurochemical indices (ex vivo)
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester); 5-HT (5-hydroxytryptamine, serotonin); 5-HT synthesis; 5-HT metabolism/turnover; Microdialysis (in vivo); 5-HT release; 5-HT_{1A} autoreceptors; Brain (rat) (Hjorth, S. (238) 357)

Neurogenic inflammation
NK_1, receptor antagonist (non-peptide); Dura mater; Migraine model; Substance P (Moussaoui, S.M. (238) 421)

Neuroleptics
Aromatic L-amino acid decarboxylase; Dopamine receptors; Striatum (Zhu, M.-Y. (238) 157)

Neuronal uptake
Fenfluramine; Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Synaptosomes (Westphalen, R.I. (238) 399)

Neuropeptide Y
Neuropeptide Y receptor sub-types; Truncated analogues; Structure-activity relationships; Binding assays; Bioassays (Dumont, Y. (238) 37)

Neuropeptide Y receptor sub-types
Neuropeptide Y; Truncated analogues; Structure-activity relationships; Binding assays; Bioassays (Dumont, Y. (238) 37)

Neurotoxins
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Synaptosomes; Neuronal uptake (Westphalen, R.I. (238) 399)

Neurotransmission
Ro 31-6930; BRL 38227; Bronchoconstriction; Cholinergic (Gater, P.R. (238) 59)

Neutrophil migration
Fenspiride; Tumour necrosis factor; Carrageenin; Endotoxin (Cunha, F.Q. (238) 47)

Nicotine
Lobeline; Cytisine; Mecamylamine; Chlorisondamine; Anxiety (Brioni, J.D. (238) 1)

Glucocorticoid receptors; Adrenal medulla; Phenylethanolamine N-methyltransferase; Catecholamines (Betito, K. (238) 273)

Nimodipine
[^{3}H]Nitrobenzylthioinosine binding; Adenosine transporters; Parietal cortex (human) (Deckert, J. (238) 131)

Nitric oxide (NO)
Substance P; Morphine; Substance P receptor antagonists; β-Adrenoceptors (Persico, P. (238) 105)

Hippocampus; Dentate gyrus; (Rat, in vivo) (Iga, Y. (238) 395)

Nitric oxide (NO), Coronary flow regulation
Hyperemia (reactive); EDRF (endothelium-derived relaxing factor); Endothelium (Domenech, R. (238) 53)

[^{3}H]Nitrobenzylthioinosine binding
Nimodipine; Adenosine transporters; Parietal cortex (human) (Deckert, J. (238) 131)

NK_1, receptor antagonist (non-peptide)
Dura mater; Neurogenic inflammation; Migraine model; Substance P (Moussaoui, S.M. (238) 421)

NMDA (N-methyl-D-aspartate)
Azelastine; Cerebral vascular disease; Ischaemia; Leukotriene (Wallis, R.A. (238) 165)

Dextromethorphan; NMDA receptor blocking agents; Ca^{2+} channel blocking agents; Na^+ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

Glycine; Pain (Millan, M.J. (238) 445)

NMDA receptor blocking agents
Dextromethorphan; NMDA (N-methyl-D-aspartate); Ca^{2+} channel blocking agents; Na^+ channel blocking agents; Nerve cell cultures; Voltage clamp (Netzer, R. (238) 209)

Noradrenaline
DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Scopolamine; Acetylcholine; Working memory; Reference memory (Ohno, M. (238) 117)

Nucleus accumbens
HA-966; (+)-MK-801; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Prefrontal cortex (Morrow, B.A. (238) 255)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin)
Aggression; TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride); Eltoprazine; Dorsal raphe (rat) (Mos, J. (238) 411)

Pain
Glycine; NMDA (N-methyl-D-aspartate) (Millan, M.J. (238) 445)

Pancreatic β-cells
H 25; H 74; Co-transport; $^{86}Rb^+$ flux (Sandström, P.-E. (238) 403)

Parietal cortex (human)
Nimodipine; [^{3}H]Nitrobenzylthioinosine binding; Adenosine transporters (Deckert, J. (238) 131)

Parkinson's disease
Ceruletide; CCK (cholecystokinin); CCK_A receptors; CCK_B receptors; Rotational behaviour (Fujisawa, M. (238) 127)

Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine); Bromocriptine; Dopamine D_2 receptor agonists; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); (Common marmoset) (Irifune, M. (238) 235)

Passive avoidance task
TRH (thyrotropin-releasing hormone); Sustained release formulation; Scopolamine; AF64A (ethylcholine aziridinium ion); Water maze task (Miyamoto, M. (238) 181)

Perchlorate
Gold ion; Ca^{2+} channels (L-type); Skeletal muscle contraction; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

Phenylethanolamine N-methyltransferase
Glucocorticoid receptors; Adrenal medulla; Nicotine; Catecholamines (Betito, K. (238) 273)

Phyllolitorin
Bombesin; Gastrin-releasing peptide (GRP); Scratching behaviour; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

Place preference
Clonidine; α_2-Adrenoceptors; (Rat) (Cervo, L. (238) 201)

Polydeoxyribonucleotides
Adenosine receptors; Purinoceptors; Adenosine; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

Prefrontal cortex
HA-966; (+)-MK-801; Excitatory amino acids; DOPAC (3,4-dihydroxyphenylacetic acid); Nucleus accumbens (Morrow, B.A. (238) 255)

Propofol
Asthma; Anaesthetics; Ketamine; Trachea; Smooth muscle (Pedersen, C.M. (238) 75)

Prostaglandin
Cl^- secretion; Colitis; cAMP; Inflammatory bowel disease; Vasoactive intestinal polypeptide (VIP) (Goldhill, J. (238) 387)

9α,11β-Prostaglandin F_2
Bronchial hyperresponsiveness; Thromboxane A_2 receptor antagonists (Kurosawa, M. (238) 335)

Prostaglandins
Fever; Glucocorticoids (Coelho, M.M. (238) 391)

Protein kinase C
5-HT (5-hydroxytryptamine, serotonin); Transmitter interaction; Desensitization; Receptor internalization (Rahman, S. (238) 173)

Purinoceptors
Adenosine receptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Defibrotide; Trachea (Bianchi, G. (238) 327)

[^{3}H]Raclopride binding
Remoxipride; Remoxipride metabolites; Antipsychotics; Dopamine receptors (Mohell, N. (238) 121)

Radiolabeled ligand binding
σ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol); (+)-SKF10,047; Stereotyped behaviour (Tanaka, M. (238) 89)

σ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride); Brain (guinea-pig) (Tanaka, M. (238) 93)

$^{86}Rb^+$ flux
Pancreatic β-cells; H 25; H 74; Co-transport (Sandström, P.-E. (238) 403)

Receptor binding
α_{1A}-Adrenoceptors; α_{1B}-Adrenoceptors; Risperidone; Antipsychotics (Sleight, A.J. (238) 407)

Receptor internalization
5-HT (5-hydroxytryptamine, serotonin); Transmitter interaction; Desensitization; Protein kinase C (Rahman, S. (238) 173)

Reference memory
DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Scopolamine; Acetylcholine; Working memory (Ohno, M. (238) 117)

Regulatory decrease in volume
Colon (rat); Cl^- channels; Leukotriene D_4 (Diener, M. (238) 217)

Remoxipride
Remoxipride metabolites; Antipsychotics; Dopamine receptors; [^{3}H]Raclopride binding (Mohell, N. (238) 121)

Remoxipride metabolites
Remoxipride; Antipsychotics; Dopamine receptors; [^{3}H]Raclopride binding (Mohell, N. (238) 121)

Reoxygenation
Angiotensin-converting enzyme inhibitors; Lisinopril; Hypoxia; Cardiomyocytes; Cardioprotection (Rabkin, S.W. (238) 81)

Reserpine
CGRP (calcitonin gene-related peptide); Gastric ulcer; Somatostatin (Clementi, G. (238) 101)

Risperidone
α_{1A}-Adrenoceptors; α_{1B}-Adrenoceptors; Antipsychotics; Receptor binding (Sleight, A.J. (238) 407)

Ro 31-6930
BRL 38227; Bronchoconstriction; Cholinergic; Neurotransmission (Gater, P.R. (238) 59)

Rotational behaviour
Ceruletide; CCK (cholecystokinin); CCK_A receptors; CCK_B receptors; Parkinson's disease (Fujisawa, M. (238) 127)

Saphenous vein (dog)
Tetrandrine; Smooth muscle (vascular); Ca^{2+}; Excitation-contraction (Kwan, C.-Y. (238) 431)

Scopolamine
DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Acetylcholine; Working memory; Reference memory (Ohno, M. (238) 117)

TRH (thyrotropin-releasing hormone); Sustained release formulation; AF64A (ethylcholine aziridinium ion); Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

Scratching behaviour
Bombesin; Gastrin-releasing peptide (GRP); Phyllolitorin; Structure-activity relationship; (Rat) (Masui, A. (238) 297)

Sedation
α_2-Adrenoceptors; Anaesthesia; Medetomidine; Atipamezole; (Cat) (Stenberg, D. (238) 241)

Skeletal muscle contraction
Gold ion; Ca^{2+} channels (L-type); Perchlorate; Sulfhydryl group; (Frog) (Nihonyanagi, K. (238) 149)

SK&F 104353
Spleen (ferret); Leukotriene receptors; ICI 198615; MK571 (Gardiner, P.J. (238) 19)

(+)-SKF10,047
σ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol); Radiolabeled ligand binding; Stereotyped behaviour (Tanaka, M. (238) 89)

Slow wave
Locus coeruleus; α_2-Adrenoceptor agonists; α_2-Adrenoceptor antagonists; High voltage spindle (Riekkinen, Jr., P. (238) 263)

Smooth muscle
Asthma; Anaesthetics; Ketamine; Propofol; Trachea (Pedersen, C.M. (238) 75)

Gamma globulin (human); Immunoglobulins; Immunoglobulin G; Spontaneous contractility (Abrahams, Z. (238) 435)

Smooth muscle (vascular)
Tetrandrine; Saphenous vein (dog); Ca^{2+}; Excitation-contraction (Kwan, C.-Y. (238) 431)

Somatostatin
CGRP (calcitonin gene-related peptide); Gastric ulcer; Reserpine (Clementi, G. (238) 101)

Spleen (ferret)
Leukotriene receptors; ICI 198615; SK&F 104353; MK571 (Gardiner, P.J. (238) 19)

Spontaneous contractility
Gamma globulin (human); Immunoglobulins; Smooth muscle; Immunoglobulin G (Abrahams, Z. (238) 435)

Stereotyped behaviour
σ Binding sites; FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol); Radiolabeled ligand binding; (+)-SKF10,047 (Tanaka, M. (238) 89)

Striatum
Aromatic L-amino acid decarboxylase; Dopamine receptors; Neuroleptics (Zhu, M.-Y. (238) 157)

Structure-activity relationship
Bombesin; Gastrin-releasing peptide (GRP); Phyllolitorin; Scratching behaviour; (Rat) (Masui, A. (238) 297)

Structure-activity relationships
Neuropeptide Y; Neuropeptide Y receptor sub-types; Truncated analogues; Binding assays; Bioassays (Dumont, Y. (238) 37)

Substance P
Nitric oxide (NO); Morphine; Substance P receptor antagonists; β-Adrenoceptors (Persico, P. (238) 105)

Substance P N-terminus; Morphine withdrawal; (Intrathecal) (Kreeger, J.S. (238) 111)

NK_1, receptor antagonist (non-peptide); Dura mater; Neurogenic inflammation; Migraine model (Moussaoui, S.M. (238) 421)

Substance P N-terminus
Substance P; Morphine withdrawal; (Intrathecal) (Kreeger, J.S. (238) 111)

Substance P receptor antagonists
Substance P; Nitric oxide (NO); Morphine; β-Adrenoceptors (Persico, P. (238) 105)

Sulfhydryl group
Gold ion; Ca^{2+} channels (L-type); Perchlorate; Skeletal muscle contraction; (Frog) (Nihonyanagi, K. (238) 149)

Sustained release formulation
TRH (thyrotropin-releasing hormone); Scopolamine; AF64A (ethylcholine aziridinium ion); Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

Synaptosomes
5-HT (5-hydroxytryptamine, serotonin); 5-HT release; d-Fenfluramine; Ca^{2+} channels (Gobbi, M. (238) 9)

Fenfluramine; Neurotoxins; 5-HT (5-hydroxytryptamine, serotonin); Nerve terminal regeneration; Neuronal uptake (Westphalen, R.I. (238) 399)

Talipexole (B-HT 920, 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine)
Bromocriptine; Dopamine D_2 receptor agonists; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease; (Common marmoset) (Irifune, M. (238) 235)

Tetrandrine
Smooth muscle (vascular); Saphenous vein (dog); Ca^{2+}; Excitation-contraction (Kwan, C.-Y. (238) 431)

TFMPP (1-(3-trifluoromethylphenyl)piperazine hydrochloride)
Aggression; Eltoprazine; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Dorsal raphe (rat) (Mos, J. (238) 411)

Thiazide diuretics
M17055; Loop diuretics; Amiloride; Free water clearance; Microperfusion study; Distal nephron segments (Shinkawa, T. (238) 317)

Thoracic aorta (rabbit)
Kinetics; Antagonism, functional; Adenosine A_2 receptors; α_1-Adrenoceptor (Wiener, H.L. (238) 65)

Thromboxane A_2 receptor antagonists
Bronchial hyperresponsiveness; 9α,11β-Prostaglandin F_2 (Kurosawa, M. (238) 335)

Trachea
Asthma; Anaesthetics; Ketamine; Propofol; Smooth muscle (Pedersen, C.M. (238) 75)

Adenosine receptors; Purinoceptors; Polydeoxyribonucleotides; Adenosine; Inosine nucleotides; Defibrotide (Bianchi, G. (238) 327)

Transmitter interaction
5-HT (5-hydroxytryptamine, serotonin); Desensitization; Receptor internalization; Protein kinase C (Rahman, S. (238) 173)

TRH (thyrotropin-releasing hormone)
Sustained release formulation; Scopolamine; AF64A (ethylcholine aziridinium ion); Passive avoidance task; Water maze task (Miyamoto, M. (238) 181)

Truncated analogues
Neuropeptide Y; Neuropeptide Y receptor sub-types; Structure-activity relationships; Binding assays; Bioassays (Dumont, Y. (238) 37)

Tryptophan
Fenfluramine; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor agonists (indirectly acting); 5-HT (pool, cytoplasmic); 5-HT release; Melatonin (Huether, G. (238) 249)

Tumour necrosis factor
Fenspiride; Carrageenin; Endotoxin; Neutrophil migration (Cunha, F.Q. (238) 47)

Vas deferens
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Videomicroscopy (guinea pig) (Eltze, M. (238) 343)

Vasoactive intestinal polypeptide (VIP)
Cl^- secretion; Colitis; cAMP; Inflammatory bowel disease; Prostaglandin (Goldhill, J. (238) 387)

Vasodilating action
MPC-1304; Ca^{2+} channel antagonists; 1,4-Dihydropyridines (Miyoshi, K. (238) 139)

Vasorelaxation
Ethanol; Acetylcholine; Endothelium; Aorta; (Rat) (Hatake, K. (238) 441)

Videomicroscopy (guinea pig)
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; Vas deferens (Eltze, M. (238) 343)

Voltage clamp
Dextromethorphan; NMDA (N-methyl-D-aspartate); NMDA receptor blocking agents; Ca^{2+} channel blocking agents; Na^+ channel blocking agents; Nerve cell cultures (Netzer, R. (238) 209)

Water maze task
TRH (thyrotropin-releasing hormone); Sustained release formulation; Scopolamine; AF64A (ethylcholine aziridinium ion); Passive avoidance task (Miyamoto, M. (238) 181)

Working memory
DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); Noradrenaline; Scopolamine; Acetylcholine; Reference memory (Ohno, M. (238) 117)

YM060
Emesis; $5\text{-}HT_3$ receptor; Cisplatin; m-Chlorophenylbiguanide (Kamato, T. (238) 369)